It was suggested by Tang et al. [18] that the combination of BCL2 and Ki-67 might allow for better prognostic information and that a high co-expression indicates a poorer prognosis with regard to PFS and OS compared to patients with low expression; however, this was true only in GCB DLBCL, while in non-GCB DLBCL only PFS was worse. The gene discussed is MKI67; the disease is diffuse large B-cell lymphoma.